FMR LLC increased its stake in shares of Celgene Co. (NASDAQ:CELG) by 14.8% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 8,160,001 shares of the biopharmaceutical company’s stock after buying an additional 1,051,528 shares during the quarter. FMR LLC owned about 1.16% of Celgene worth $648,067,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Johnson Financial Group Inc. lifted its holdings in shares of Celgene by 4.5% in the 2nd quarter. Johnson Financial Group Inc. now owns 13,100 shares of the biopharmaceutical company’s stock valued at $1,040,000 after purchasing an additional 567 shares during the last quarter. Wetherby Asset Management Inc. raised its stake in Celgene by 5.4% during the 2nd quarter. Wetherby Asset Management Inc. now owns 11,857 shares of the biopharmaceutical company’s stock valued at $942,000 after acquiring an additional 603 shares during the last quarter. Tompkins Financial Corp raised its stake in Celgene by 3.8% during the 2nd quarter. Tompkins Financial Corp now owns 18,059 shares of the biopharmaceutical company’s stock valued at $1,434,000 after acquiring an additional 656 shares during the last quarter. Coastline Trust Co raised its stake in Celgene by 14.5% during the 2nd quarter. Coastline Trust Co now owns 5,370 shares of the biopharmaceutical company’s stock valued at $427,000 after acquiring an additional 680 shares during the last quarter. Finally, BancorpSouth Bank raised its stake in Celgene by 11.8% during the 2nd quarter. BancorpSouth Bank now owns 6,591 shares of the biopharmaceutical company’s stock valued at $523,000 after acquiring an additional 697 shares during the last quarter. Institutional investors own 73.11% of the company’s stock.

CELG has been the subject of a number of analyst reports. Sanford C. Bernstein raised Celgene from a “market perform” rating to an “outperform” rating and set a $102.00 target price for the company in a research note on Wednesday, May 23rd. Zacks Investment Research cut Celgene from a “hold” rating to a “sell” rating in a report on Wednesday, July 18th. Mizuho restated a “buy” rating and issued a $129.00 price target on shares of Celgene in a report on Tuesday, July 31st. Canaccord Genuity restated a “buy” rating on shares of Celgene in a report on Wednesday, May 30th. Finally, SunTrust Banks lowered their price target on Celgene from $106.00 to $96.00 and set a “hold” rating on the stock in a report on Tuesday, May 29th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, twenty have assigned a buy rating and two have assigned a strong buy rating to the stock. Celgene presently has a consensus rating of “Buy” and a consensus price target of $121.85.

In related news, Director Ernest Mario sold 12,000 shares of Celgene stock in a transaction dated Thursday, August 9th. The stock was sold at an average price of $92.32, for a total value of $1,107,840.00. Following the completion of the transaction, the director now directly owns 44,413 shares in the company, valued at $4,100,208.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John H. Weiland purchased 5,575 shares of the firm’s stock in a transaction that occurred on Tuesday, August 7th. The stock was purchased at an average price of $89.73 per share, with a total value of $500,244.75. The disclosure for this purchase can be found here. 0.39% of the stock is owned by company insiders.

NASDAQ:CELG traded down $1.57 during mid-day trading on Friday, hitting $87.17. The company had a trading volume of 3,500,752 shares, compared to its average volume of 4,006,216. The company has a debt-to-equity ratio of 5.76, a current ratio of 1.52 and a quick ratio of 1.40. Celgene Co. has a 1 year low of $74.13 and a 1 year high of $147.17. The firm has a market capitalization of $61.05 billion, a PE ratio of 12.74, a price-to-earnings-growth ratio of 0.52 and a beta of 1.32.

Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, July 26th. The biopharmaceutical company reported $2.16 earnings per share for the quarter, beating the consensus estimate of $2.11 by $0.05. The company had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.70 billion. Celgene had a return on equity of 87.28% and a net margin of 19.81%. The company’s revenue was up 16.6% on a year-over-year basis. During the same period last year, the firm earned $1.82 earnings per share. equities analysts anticipate that Celgene Co. will post 7.64 EPS for the current year.

Celgene declared that its board has approved a share buyback program on Thursday, May 24th that permits the company to repurchase $3.00 billion in shares. This repurchase authorization permits the biopharmaceutical company to repurchase up to 5.4% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its shares are undervalued.

About Celgene

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

See Also: What kind of dividend yield to CEF’s pay?

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.